Stalicla
Geneva, Switzerland
Stalicla is a precision medicine biotechnology company focused on brain disorders. Their DEPI platform utilizes multiomics, patient data, and artificial intelligence to identify biological subgroups within neurodevelopmental and neuropsychiatric conditions. This enables matching patients with appropriate drug treatments. The company has advanced assets like Mavoglurant into clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorders. They partner with major pharmaceutical companies and aim to revolutionize brain disease treatment through phenotyping-based approaches.
Company Info
- Founded
- 2017
- Website
- stalicla.com
Only accessible to MedStartr community members.
Join nowWhat do you think of Stalicla?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.